Fundz

Ovid Therapeutics

New York, New York, United States · Biotechnology, Healthcare, Health Care

Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. For those who need relief, we must succeed—their hopes are our aspirations. We act with urgency, ingenuity and integrity as we seek a future free of seizures. At Ovid, we are pursuing small molecule compounds with untapped potential.

Key facts

Headquarters
New York, New York, United States
Employees
23
Industries
Biotechnology, Healthcare, Health Care
Status
Public (OVID)
Website
ovidtherapeutics.com
LinkedIn
Company page

Recent activity at Ovid Therapeutics

  • : Ovid Therapeutics Inc. Appoints Kevin Norrett as Chief Business Officer and Promotes Charles Carter to CFO
  • : Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer
  • : SEC 8-K (5.02): On July 5, 2026, Ovid Therapeutics Inc. announced the departure of Jeffrey Rona, the Chief Business and Financial Officer, effective July 6, 2026. Following Mr. Rona's departure, Charles Carter was appointed as the new Chief Financial Officer. Mr. Rona's exit was mutual and not the result of any disagreements regarding the company's financial practices. Mr. Carter, previously Senior Vice President of Finance, will receive an annual salary of $460,000 along with a bonus potential and a stock grant of 50,000 shares, which will vest over two years contingent on his continued service. This management change is strategic as it includes new leadership in key financial roles and a defined compensation structure for Mr. Carter.
  • : SEC 8-K (5.02): On May 29, 2026, the Board of Directors of Ovid Therapeutics Inc. approved the appointment of Dr. Anna Greka as a Class III director, effective June 15, 2026, increasing the Board size to seven directors. Dr. Greka, age 50, is a distinguished Professor of Medicine at Harvard Medical School with extensive roles in various biopharmaceutical initiatives. She will also serve on the Compensation and Science and Technology Committees of the Board. Compensation for Dr. Greka's service will align with the company’s non-employee director compensation policy, and there's a standard indemnification agreement regarding her service-related expenses. This appointment is strategically significant for Ovid Therapeutics as it enhances the Board's expertise in biotechnology and therapeutics.
  • : SEC 8-K (8.01): On April 17, 2026, Ovid Therapeutics Inc. reported that the Series A Warrants issued in connection with its October 2025 private placement expired. Investors elected to exercise 33,597,860 of these warrants into shares of common stock at $1.40 per share, along with 4,883,464 pre-funded warrants at $1.399 per share. This resulted in gross proceeds of approximately $53.9 million for the company. The expiration and exercise of the warrants are significant as they impact the company's capital structure and financial position, enabling Ovid to raise substantial funds to support its operations and growth initiatives.
  • : SEC 8-K (1.01): On March 17, 2026, Ovid Therapeutics Inc. entered into a Securities Purchase Agreement with various investors to issue and sell a total of 19,154,321 shares of its common stock at $2.01 per share and pre-funded warrants for up to 10,701,710 shares at $2.009 each. This private placement is expected to yield gross proceeds of $60 million, which will be used to support the development of OV329 for various conditions as well as general R&D expenses. The transaction is set to close on or about March 19, 2026, subject to customary closing conditions. Additionally, a Registration Rights Agreement was executed concurrently, requiring the filing of a registration statement with the SEC within 30 business days post-closing, with specific penalties for delays.
  • : SEC 8-K (8.01): Ovid Therapeutics Inc. issued a press release on December 18, 2025, announcing results from its Phase 1 study of OV350. This study represents a significant milestone for the company as it investigates the therapeutic potential of OV350, which may have implications for future drug development and strategy. The press release is included as Exhibit 99.1 in the filing. No financial amounts were disclosed in the filing.
  • : SEC 8-K (5.02): On November 11, 2025, the Company appointed Margaret 'Meg' Alexander as Chief Executive Officer, effective January 1, 2026, succeeding Dr. Jeremy M. Levin, who will continue as Executive Chairman. Ms. Alexander will maintain her role as President but will no longer serve as Chief Operating Officer. In conjunction with her appointment, an Amended and Restated Employment Agreement was entered into, effective January 1, 2026, providing Ms. Alexander with an annual salary of $625,000, a target cash bonus of 55% of her salary, reimbursement for legal fees up to $35,000, and a stock option to purchase 890,000 shares with a vesting schedule. This transition reflects strategic leadership changes within the Company as it continues to evolve under new management.
  • : SEC 8-K (5.07): On December 11, 2025, Ovid Therapeutics Inc. conducted a special meeting of stockholders where various proposals were voted on. As of the record date, October 31, 2025, the company had 71,212,353 shares of common stock outstanding, with 38,044,680 shares (approximately 53.42%) present to constitute a quorum for the meeting. The specifics of the proposals and voting results were referenced, with further details provided in a definitive proxy statement filed on November 7, 2025. This meeting and the outcomes may have strategic implications for company governance and future decision-making processes.
  • : SEC 8-K (8.01): On April 17, 2026, Ovid Therapeutics Inc. reported the expiration of its Series A Warrants issued during an October 2025 private placement. A total of 38,481,325 common shares were underlying these warrants, of which investors exercised 33,597,860 shares at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per share. This transaction resulted in gross proceeds of approximately $53.9 million for the Company. The exercise of the warrants reflects investor confidence and provides significant capital to support Ovid Therapeutics' ongoing operations and strategic objectives.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Ovid Therapeutics funding history

DateRoundAmount
Jan 2017Venture$25.9M
Aug 2015Venture$75.0M

Leadership

  • Karen Bernstein, Director
  • Douglas Williams, Director
  • Bart Friedman, Director
  • Jeremy Levin, Executive Officer, Director
  • Matthew During, Executive Officer, Director
  • Charles Carter, Chief Financial Officer
  • Kevin Norrett, Chief Business Officer
  • Barbara Salzmann, Medizinischer Kosmetiker
  • Harish Vasudevan, Associate Director, Program Management and Leadership
  • Jatinder Singh, Senior Research Fellow
  • Naomi Shaw, Senior Director, Accounting
  • Simon Kelner, Senior Advisor

Verified email and direct lines for Ovid Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Ovid Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Companies similar to Ovid Therapeutics

About Ovid Therapeutics: questions and answers

What does Ovid Therapeutics do?

Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for epilepsies and brain conditions. For those who need relief, we must succeed—their hopes are our aspirations. We act with urgency, ingenuity and integrity as we seek a future free of seizures. At Ovid, we are pursuing small molecule compounds with untapped potential.

Where is Ovid Therapeutics headquartered?

Ovid Therapeutics is headquartered in New York, New York, United States.

How many employees does Ovid Therapeutics have?

Ovid Therapeutics has about 23 employees.

Has Ovid Therapeutics raised funding?

Yes. Fundz has recorded 2 funding events for Ovid Therapeutics. The most recent, $25.9M, was in Jan 2017.

What is the latest news on Ovid Therapeutics?

On Jul 14, 2026, Ovid Therapeutics Inc. Appoints Kevin Norrett as Chief Business Officer and Promotes Charles Carter to CFO

Is Ovid Therapeutics a public company?

Yes. Ovid Therapeutics is publicly traded under the ticker OVID.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Ovid Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.